ESLA logo
ESLA NASDAQ US

Estrella Immunopharma, Inc. - Common Stock

Healthcare · Biotechnology Website · IPO Jul 2021
$1.05
▲ +$0.00 (+0.00%)
Vol 10K
2
Quality Score
fail
Mkt Cap
$58.9M
ROE
-259.1%
D/E
0.00
Beta
0.56
52W
$1–$3

Wall Street Consensus

7 analysts · Apr 2026
2
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating

Price Chart

Earnings

Beat rate: 50.0%
Quarter EPS Est EPS Act Surprise
Dec 2025 $-0.18 $-0.35 $-0.17
Sep 2025 $-0.19 $-0.13 +$0.06
Jun 2025 $-0.11 $-0.15 $-0.04
Mar 2025 $-0.11 $-0.06 +$0.05

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -259.1% -259.1% -259.1% -259.1% -259.1%
P/E (TTM)
Net Margin
Gross Margin
D/E Ratio 0.00 0.00 0.00 0.00 0.00
Current Ratio 0.16 0.22 0.16 0.16 0.16 0.15

Key Ratios

ROA (TTM)
-446.7%
P/B
302.1
EPS (TTM)
$-0.37
52W High
$3.15
52W Low
$0.73
$0.73 52-Week Range $3.15

How does ESLA compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

ESLA AAPG ABEO ABOS ABP

ESLA valuation vs Biotechnology peers

P/E ratio
0% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0% below peers (12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
302.1
12179% above peers (2.5)
vs Peers
vs Industry
Overvalued
Div yield
0% below peers (0.0%)
vs Peers
vs Industry
Low yield

ESLA profitability vs Biotechnology peers

ROE
-259.1%
285% below peers (-67.3%)
vs Peers
vs Industry
Weak
Net margin
0% below peers (-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
0% below peers (78.6%)
vs Peers
vs Industry
In line
ROA
-446.7%
856% below peers (-46.7%)
vs Peers
vs Industry
Weak

ESLA financial health vs Biotechnology peers

D/E ratio
0.0
0% below peers (0.0)
vs Peers
vs Industry
Low debt
Current ratio
0.2
97% below peers (4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.6
42% below peers (1.0)
vs Peers
vs Industry
More volatile

ESLA fundamentals radar

ESLA Peer median Industry

ESLA profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

ESLA vs peers: key metrics